We are live on ! Find out more
NPCE icon

Neuropace
NPCE

32 hedge funds and large institutions have $71.4M invested in Neuropace in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.45% more ownership

Funds ownership: 74.42% → 74.88% (+0.45%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

20% less funds holding

Funds holding: 40 → 32 (-8)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

52% less capital invested

Capital invested by funds: $150M → $71.4M (-$78.1M)

57% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 14

Holders
32
Holders Change
-8
Holders Change %
-20%
% of All Funds
0.54%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
6
Reduced
14
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$6.27M
2
OM
Opaleye Management
Massachusetts
+$595K
3
Millennium Management
Millennium Management
New York
+$554K
4
American Century Companies
American Century Companies
Missouri
+$254K
5
E
Ergoteles
New York
+$230K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.07M
2
KCM
Kornitzer Capital Management
Kansas
-$1.64M
3
RCM
Revelation Capital Management
California
-$876K
4
State Street
State Street
Massachusetts
-$504K
5
Norges Bank
Norges Bank
Norway
-$476K
Name Holding Trade Value Shares
Change 		Change in
Stake
KL
1
KCK Ltd
Bermuda
$27.8M – – –
SCM
2
Soleus Capital Management
Connecticut
$11.6M +$66K +10,000 +0.4%
Morgan Stanley
3
Morgan Stanley
New York
$9.83M +$6.27M +949,405 +92%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$7.02M +$76.9K +11,645 +0.8%
American Century Companies
5
American Century Companies
Missouri
$2.84M +$254K +38,494 +7%
BG
6
Bellevue Group
Switzerland
$2.51M – – –
Millennium Management
7
Millennium Management
New York
$2.51M +$554K +83,877 +20%
NCM
8
Nantahala Capital Management
Connecticut
$2.37M -$45.3K -6,865 -1%
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.35M -$245K -37,172 -12%
RCM
10
Revelation Capital Management
California
$1.23M -$876K -132,578 -35%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$739K -$396K -59,977 -29%
OM
12
Opaleye Management
Massachusetts
$446K +$595K +90,100 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$324K -$339K -51,298 -44%
E
14
Ergoteles
New York
$172K +$230K +34,800 New
BCM
15
Bridgeway Capital Management
Texas
$129K +$173K +26,148 New
State Street
16
State Street
Massachusetts
$111K -$504K -76,266 -77%
BlackRock
17
BlackRock
New York
$109K -$2.07M -313,116 -93%
Citadel Advisors
18
Citadel Advisors
Florida
$108K +$143K +21,692 New
Renaissance Technologies
19
Renaissance Technologies
New York
$63K +$83.9K +12,700 New
Northern Trust
20
Northern Trust
Illinois
$56K -$323K -48,909 -81%
O
21
OrbiMed
New York
$19.9K – – –
Barclays
22
Barclays
United Kingdom
$17K -$7.61K -1,152 -25%
Bank of America
23
Bank of America
North Carolina
$16K -$9.27K -1,403 -31%
Nisa Investment Advisors
24
Nisa Investment Advisors
Missouri
$15K +$19.8K +3,000 New
CSS
25
Cubist Systematic Strategies
Connecticut
$3K +$4.18K +633 +3,517%
1
2

NPCE Hedge Fund Activity: Q2 2022 in Review

32 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q2 2022, worth a combined $71.4M — down 52% from $150M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of NPCE and 8 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 6 added.

The largest buyer was Morgan Stanley, adding an estimated $6.27M. The largest seller was BlackRock, cutting an estimated $2.07M.

  • 32 institutional investors held Neuropace (NPCE) as of Q2 2022, down from 40 in Q1 2022.
  • Funds reported $71.4M of Neuropace stock for Q2 2022, down 52% quarter-over-quarter.
  • 8 funds opened new Neuropace positions in Q2 2022 and 15 closed out, a net change of -7 holders.
  • The largest Neuropace buyer in Q2 2022 was Morgan Stanley, an estimated $6.27M added.
  • The largest Neuropace seller in Q2 2022 was BlackRock, an estimated $2.07M sold.

Based on aggregated 13F filings for Q2 2022.